Результаты поиска

Cost-effectiveness analysis of molecular reflex testing-based targeted therapy in non-small cell lung cancer from a German healthcare payer perspective using a decision tree model.

BACKGROUND: Reflex testing (RT) - pathologist-initiated molecular testing performed at non-small cell lung cancer (NSCLC) diagnosis - enables rapid identification of actionable genomic alterations for targeted therapy (TT) selection. Despite national and international guideline recommendations, approximately 15% of patients with advanced NSCLC in Germany remain untested for driver mutations. The portion of untested patients in early stages is likely to be even higher. OBJECTIVE: This study simulated the clinical and economic impact of introducing RT for untested NSCLC patients under different

Annual versus less frequent mammographic surveillance in people with breast cancer aged 50 years and older in the UK (Mammo-50): cost-effectiveness and budget impact analysis.

BACKGROUND: There is limited evidence on the optimal frequency of mammogram surveillance. At 5-year follow-up, the Mammo-50 trial found that, in patients aged 50+ and 3 years post diagnosis, less frequent mammograms were non-inferior to annual mammograms for breast-cancer-specific-survival, recurrence-free interval and overall survival. METHODS: A within-trial cost-effectiveness analysis compared annual versus less frequent mammogram surveillance over 5 years from healthcare and societal perspectives. Hospital Episodes Statistics captured hospital-based resource use. Health-related quality of…

Cost-effectiveness of low-dose CT lung cancer screening among individuals that have ever smoked in Norway: A model-based analysis using NELSON trial criteria and outcomes.

Clinical trials have shown that low-dose computed tomography (LDCT) screening reduces lung cancer mortality among selected groups of ever-smokers. Nordic countries have yet to implement lung cancer screening programs in part due to limited evidence on the associated health and economic consequences. This study evaluated the cost-effectiveness of LDCT screening compared with no screening for Norwegian individuals aged 50-74 years who ever smoked, using the Dutch-Belgian NELSON screening-eligibility criteria and trial outcomes. In addition, we evaluated the potential need and value of additional

The Role of Compliance and Cost in Regulating the Effectiveness of Notched Sound Therapy Phone Applications for Tinnitus Relief: Updated Analysis of a Prospective Randomized Control Trial.

BACKGROUND: Notched sound therapy (NST) is a mobile application that has been shown to provide tinnitus relief by reducing dysfunctional auditory cortex reorganization. This study aimed to evaluate the role of compliance with notched sound therapy (NST) on the effectiveness of reducing tinnitus symptoms. METHODS: A prospective randomized control trial was performed in patients older than or equal to 18 years at a tertiary referral center. Patients were randomized at enrollment to either the NST group and given a free subscription to the NST mobile application or the standard of care (SOC) gro

Effects of oral zinc supplementation in the prevention of community-acquired pneumonia in colombian children: an economic evaluation : Short running title: Cost-effectiveness analysis oral zinc supplementation.

INTRODUCTION:  Oral zinc supplementation is a well-known intervention, widely used to prevent infectious diseases. However, it is also necessary to demonstrate that it achieves the maximum benefit at the lowest possible cost in pneumonia in children, particularly in low- and middle-income countries. This economic evaluation aims to estimate the cost-utility and cost-effectiveness of zinc supplementation for the prevention of community-acquired pneumonia in children aged 1 to 6 years in Colombia.  MATERIALS AND METHODS: Using the decision tree analysis, we estimated the expected benefits and co

Анализ экономической эффективности даратумумаба плюс бортезомиба, мелфалана и преднизона против бортезомиба, мелфалана и преднизона у пациентов с недавно поставленным диагнозом множественной миеломы, не имеющей права на трансплантацию стволовых клеток.

Цель этого исследования заключалась в изучении экономической эффективности бортезомиба, мелфалана и преднизона с использованием даратумумаба (D-VMP) против борцезомиба, мелфалана и преднизона (VMP) у пациентов с недавно поставленным диагнозом множественной миеломы (NDMM), которые были лишены права на автоматическую трансплантацию стволовых клеток (ASCT). Была разработана модель MetodsA Маркова и three Включены только состояние здоровья, отсутствие прогресса в выживании (ПФС), прогрессивные заболевания (ПЗ) и смерть. Продолжительность цикла была установлена следующим образом: 1.5 месяцев и врем

Совпадение в полном тексте источника
… Cost-Effectiveness Analysis of Adding Daratumumab to Bortezomib, Melphalan, and Prednisone for Untreated Multiple Myeloma. Front Pharmacol. 2021;12:608685. doi: 10.3389/fphar.2021.608685. 25. Li S, Li J, Peng L, et al. … First-line Daratumumab in Addition to Chemotherapy for Newly Diagnosed Multiple Myeloma Patients Who are Transplant Ineligible: A Cost-Effectiveness Analysis. Clin Ther. 2021;43:1253–64. doi: 10.1016/j.clinthera.2021.05.015. …

Once-weekly semaglutide versus placebo for the treatment of type 2 diabetes and chronic kidney disease in Denmark: A long-term cost-effectiveness analysis based on FLOW.

BACKGROUND: The FLOW clinical trial recently demonstrated that the glucagon-like peptide-1 receptor agonist once-weekly semaglutide 1 mg was associated with kidney- and cardio-protective effects (the latter already shown in the SUSTAIN 6 trial) compared with placebo, both in addition to standard of care (SoC), in people with type 2 diabetes (T2D) and chronic kidney disease (CKD). This study assessed the long-term cost-effectiveness of semaglutide versus placebo in people with T2D and CKD in Denmark, based on outcomes from FLOW. METHODS: Life expectancy, quality-adjusted life expectancy, cumul

Cost-effectiveness analysis comparing QuantiFERON test and tuberculin skin test for the diagnosis of latent tuberculosis infection in immunocompetent children under 15 years of age in Colombia.

OBJECTIVE: To determine the cost-effectiveness of the QuantiFERON (QFT) test versus the tuberculin skin test (TST) in diagnosing latent tuberculosis infection (LTBI) in immunocompetent children under 15 years of age who are in contact with active tuberculosis (TB) patients in the context of the Colombian healthcare system. DESIGN: Health economic evaluation. Decision tree over a horizon of <1 year. SETTING: From the perspective of the Colombian healthcare system, the direct healthcare costs related to tests were considered, and diagnostic performance was used as a measure of effectiveness. T

Cost-effectiveness analysis of transcatheter aortic valve implantation versus surgical aortic valve replacement in patients with severe aortic stenosis at low risk of surgical mortality in Sweden.

BACKGROUND: Transcatheter aortic valve implantation (TAVI) has shown similar or improved clinical outcomes compared with surgical aortic valve replacement (SAVR) in patients with symptomatic severe aortic stenosis at low risk for surgical mortality. This cost-utility analysis compared TAVI with SAPIEN 3 versus SAVR in symptomatic severe aortic stenosis patients at low risk of surgical mortality from the perspective of the Swedish healthcare system. METHODS: A published, two-stage, Markov-based cost-utility model that captured clinical outcomes from the Swedish Web-system for Enhancement and D

Effect of living in well-insulated warm houses on hypertension and cardiovascular diseases based on a nationwide epidemiological survey in Japan: a modelling and cost-effectiveness analysis.

INTRODUCTION: Cardiovascular diseases (CVDs) are more prevalent in colder homes, partly due to cold-induced high blood pressure (BP). While thermal insulation and heating are rational strategies to mitigate cold exposure, the high initial and running costs pose significant barriers. Therefore, this study aims to evaluate the cost-effectiveness of living in well-insulated warm houses. METHODS: An economic model was developed based on the indoor temperature-BP and BP-CVDs relationships. Five scenarios were outlined: a base scenario (Scenario 0: the most prevalent thermal insulation level (Grade

Cost-effectiveness analysis of budesonide/formoterol SMART therapy versus salmeterol/fluticasone plus as-needed SABA among patients ≥12 years with moderate asthma from the Chinese societal perspective.

OBJECTIVES: To evaluate the cost-effectiveness of budesonide/formoterol reliever and maintenance therapy compared with salmeterol/fluticasone plus salbutamol as reliever therapy for asthma patients ≥12 years from the societal perspective in China. METHODS: A Markov model was developed with three health states (non-exacerbation, exacerbation, and death) with a lifetime horizon. The exacerbation rates were obtained from a prospective cohort study conducted in Chinese asthma patients. Healthcare resources utilization data were estimated based on current clinical asthma management guidelines. Ast

Assessing thresholds of resistance prevalence at which empiric treatment of gonorrhea should change among men who have sex with men in the US: A cost-effectiveness analysis.

BACKGROUND: Since common diagnostic tests for gonorrhea do not provide information about susceptibility to antibiotics, treatment of gonorrhea remains empiric. Antibiotics used for empiric therapy are usually changed once resistance prevalence exceeds a certain threshold (e.g., 5%). A low switch threshold is intended to increase the probability that an infection is successfully treated with the first-line antibiotic, but it could also increase the pace at which recommendations are switched to newer antibiotics. Little is known about the impact of changing the switch threshold on the incidence

A Model-Based Cost-Effectiveness Analysis of Long-Acting Monoclonal Antibody (Tixagevimab and Cilgavimab: Evusheld) Preventive Treatment for High-Risk Populations Against SARS-CoV-2 in Korea.

BACKGROUND: Tixagevimab and cilgavimab (Evusheld) administration is a recommended strategy for unvaccinated patients with immunocompromised conditions and severe allergic reaction conditions to protect high-risk individuals and control the coronavirus disease 2019 (COVID-19) epidemic. We estimated the cost-effectiveness of Evusheld in key risk populations: 1) immunocompromised (vaccinated/unvaccinated), 2) severe allergic reaction, and 3) unvaccinated elderly high-risk groups. METHODS: Based on the estimated target risk group population, we used a model of COVID-19 transmission to estimate th

A cost-effectiveness analysis of patiromer in the UK: evaluation of hyperkalaemia treatment and lifelong RAASi maintenance in chronic kidney disease patients with and without heart failure.

BACKGROUND: Chronic kidney disease (CKD) patients with and without heart failure (HF) often present with hyperkalaemia (HK) leading to increased risk of hospitalisations, cardiovascular related events and cardiovascular-related mortality. Renin-angiotensin-aldosterone system inhibitor (RAASi) therapy, the mainstay treatment in CKD management, provides significant cardiovascular and renal protection. Nevertheless, its use in the clinic is often suboptimal and treatment is frequently discontinued due to its association with HK. We evaluated the cost-effectiveness of patiromer, a treatment known

Cost-effectiveness analysis of recombinant human follicle-stimulating hormone alfa(r-hFSH) and urinary highly purified menopausal gonadotropin (hMG) based on data from a large German registry.

This was a retrospective real-world evidence analysis of the costs per live birth for reference recombinant human follicle-stimulating hormone alfa (r-hFSH-alfa) versus highly purified urinary human menopausal gonadotropin (hMG-HP), based on data from a German in vitro fertilization registry (RecDate). Pregnancy and live birth rates from the RecDate real-world evidence study over three complete assisted reproductive technology (ART) cycles using the same gonadotropin drug were used as clinical inputs. Costs related to ART treatment and to drugs were obtained from public sources. Treatment with

Cost-effectiveness analysis of KTE-X19 CAR T therapy versus real-world standard of care in patients with relapsed/refractory mantle cell lymphoma post BTKi in England.

AIMS: The objective of this study is to estimate the cost-effectiveness of KTE-X19 versus standard of care (SoC) in the treatment of patients with relapsed/refractory (R/R) mantle cell lymphoma (MCL) post-Bruton tyrosine kinase inhibitor (BTKi) treatment from a UK healthcare perspective. MATERIALS AND METHODS: A three-state partitioned survival model (pre-progression, post-progression and death) with a cycle length of one month was used to extrapolate progression-free and overall survival over a lifetime horizon. Population inputs along with KTE-X19 (brexucabtagene autoleucel) efficacy and sa

The Cost-Effectiveness Analysis of Transplant-Ineligible Myeloma Patients with Bortezomib plus Thalidomide plus Dexamethasone (VTD) or Bortezomib plus Melphalan plus Prednisolone (VMP) Treatment in Southern Taiwan.

BackgroundThis study aimed to evaluate the cost-effectiveness of treating transplant-ineligible myeloma patients with either a bortezomib plus thalidomide plus dexamethasone (VTD) or a bortezomib plus melphalan plus prednisolone (VMP) treatment in Taiwan.MethodsNewly diagnosed, transplant-ineligible myeloma patients with VTD or VMP therapy were enrolled from two medical centers in southern Taiwan. Quality-adjusted life years (QALYs) were used as the measurement unit of the effectiveness evaluation, and the incremental cost-effectiveness ratio (ICER) was used for comparison between the two grou

Совпадение в полном тексте источника
… In the study, we applied a standard cost-effectiveness analysis (CEA) methodology that compared the medical costs and health consequences by different regimens [ 12 , 14 ]. … A cost-effectiveness analysis of real-world treatment for elderly patients with multiple myeloma using a full disease model Eur. J. Haematol. 2016 96 198 208 10.1111/ejh.12571 25892333 11. Chen W. Yang Y. Chen Y. Du F. Zhan H. …

A cost-effectiveness analysis of reverse total shoulder arthroplasty compared with locking plates in the management of displaced proximal humerus fractures in the elderly: the DelPhi trial.

AIM: To evaluate the cost-effectiveness of surgical treatment with reverse total shoulder arthroplasty (RTSA) compared with open reduction and internal fixation (ORIF) with a locking plate for patients 65-85 years old with a displaced proximal humerus fracture. METHODS: A cost-utility analysis was conducted alongside a multicenter randomized controlled trial, taking a health care perspective. A total of 124 patients with displaced proximal humerus fractures were randomized to treatment with RTSA (n = 64) or ORIF (n = 60) during a 2-year period. The outcome measure was quality-adjusted life ye

Cost-effectiveness analysis of NEPA, a fixed-dose combination of netupitant and palonosetron, for the prevention of highly emetogenic chemotherapy-induced nausea and vomiting: an international perspective.

PURPOSE: The aim of this study was to assess the cost-effectiveness of NEPA, a fixed-dose combination of oral netupitant (300 mg) and palonosetron (0.5 mg), compared to available treatments in Spain after aprepitant generic introduction in the market, and to discuss results in previously performed analyses in different wordwide settings. METHODS: A Markov model including three health states, complete protection, complete response at best and incomplete response, was used to evaluate the cost-effectiveness of NEPA versus common treatment options in Spain during 5 days after chemotherapy. Incre

First-line Treatment with Empagliflozin and Metformin Combination Versus Standard Care for Patients with Type 2 Diabetes Mellitus and Cardiovascular Disease in Qatar. A Cost-Effectiveness Analysis.

Sodium-glucose cotransporter 2 (SGLT2) inhibitors have shown to reduce cardiovascular events and mortality in patients with type 2 diabetes mellitus (T2DM), but they are currently not used as first-line therapy in clinical practice. This study sought to evaluate the cost-effectiveness of first-line empagliflozin plus standard care for patients with newly diagnosed T2DM and existing cardiovascular disease (CVD). A decision-analytic Markov model with one-year cycles and a lifetime time horizon was developed from the perspective of the Qatari healthcare system to compare first-line empagliflozin